8-K: Teleflex Reports Q1 2025 Financial Results, Updates Full-Year Outlook Amid Tariff Concerns

Teleflex announces its first quarter 2025 financial results, highlighting revenue and EPS figures while adjusting full-year guidance due to the impact of tariffs and strategic separation activities.

Summary

• Teleflex reported first quarter revenues of $700.7 million, a 5.0% decrease compared to the prior year, or a 3.8% decrease on an adjusted constant currency basis.
• GAAP diluted EPS from continuing operations was $2.07, compared to $0.33 in the prior year period.
• Adjusted diluted EPS from continuing operations was $2.91, compared to $3.21 in the prior year period.
• The company is raising its GAAP revenue growth guidance range for 2025 to 1.28% to 2.28%.
• Teleflex is maintaining its adjusted constant currency revenue growth guidance range of 1.00% to 2.00%.
• The company expects an impact from tariffs of approximately $55 million in 2025, which will be recorded in cost of goods sold.
• Due to tariffs and separation/acquisition-related expenses, Teleflex is lowering its GAAP EPS guidance range to $6.51 to $6.91.
• The adjusted diluted EPS guidance range is lowered to $13.20 to $13.60, partially offset by a $300 million share repurchase, expense control, and a small foreign exchange benefit.
• The company completed a $300 million accelerated share repurchase on April 9, 2025.
• Teleflex is actively exploring options for NewCo, including a potential sale, in parallel with the potential spin transaction.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is raising GAAP revenue growth guidance, it is lowering EPS guidance due to tariffs and separation costs. The exploration of strategic options for NewCo adds uncertainty.

Positives

• Teleflex raised its full year 2025 revenue growth outlook on a GAAP basis to a range of 1.28% to 2.28%.
• The company completed a $300 million accelerated share repurchase on April 9, 2025.
• Teleflex received FDA 510(k) clearance of the AC3 RangeTM intra-aortic balloon pump (IABP).
• Teleflex received FDA clearance of expanded indication to include all grades of internal and external bleeding for QuikClot Control+TM.

Negatives

• Revenues decreased 5.0% year-over-year on a GAAP basis.
• Adjusted revenue decreased 3.8% year-over-year on a constant currency basis.
• The company lowered its full year 2025 GAAP diluted earnings per share from continuing operations outlook to a range of $6.51 to $6.91.
• The company lowered its full year 2025 adjusted diluted earnings per share from continuing operations guidance to a range of $13.20 to $13.60.
• The company expects an impact from tariffs of approximately $55 million in 2025, which will be recorded in cost of goods sold.

Risks

• The company faces risks related to tariffs, which are expected to impact 2025 results by $55 million.
• The separation of Teleflex into two companies involves risks including customer and shareholder reaction, disruption to business relationships, and significant transaction costs.
• The company faces risks related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, including receipt of certain regulatory approvals.
• The company faces risks related to demand for and market acceptance of new and existing products.
• The company faces risks related to global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities.

Future Outlook

Teleflex has updated its full-year 2025 guidance, raising GAAP revenue growth while lowering EPS guidance due to tariffs and separation costs; the company is also exploring strategic options for NewCo.

Management Comments

• 'Our performance for the first quarter was in line with our expectations,' said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer.
• He also stated that without the impact of tariffs, full-year results would fall within previously stated guidance ranges.
• Management is evaluating strategies to mitigate tariff exposure and remains focused on executing the plan for the year.
• Management are continuing to actively explore all options for NewCo with the goal of maximizing shareholder value, including evaluating the potential sale of NewCo in parallel with the potential spin transaction.

Industry Context

Teleflex's announcement comes amid broader industry trends of medical device companies facing challenges from tariffs, supply chain disruptions, and regulatory changes, while also pursuing strategic initiatives like spin-offs and acquisitions to enhance shareholder value.

Comparison to Industry Standards

• Medtronic, a major player in the medical device industry, reported a revenue decline of 1.2% in its most recent quarter, indicating a similar trend of revenue challenges.
• Stryker, another key competitor, reported organic sales growth of 9.8%, showcasing a stronger performance compared to Teleflex's adjusted constant currency revenue decline of 3.8%.
• Johnson & Johnson's MedTech segment reported operational sales growth of 7.9%, suggesting a more robust growth trajectory than Teleflex.
• The impact of tariffs on Teleflex's earnings is a concern shared by other medical device companies with global supply chains, such as Boston Scientific, which has also cited tariffs as a headwind.
• Teleflex's strategic decision to separate into two companies mirrors similar moves by other diversified healthcare companies, such as Baxter International's spin-off of its biopharmaceutical business, demonstrating a trend towards greater focus and specialization.

Stakeholder Impact

• Shareholders may be impacted by the lowered EPS guidance and the uncertainty surrounding the NewCo separation and potential sale.
• Employees may be affected by the separation of Teleflex into two companies and any potential restructuring activities.
• Customers may experience changes in product offerings and service as a result of the separation and acquisition activities.
• Suppliers may be impacted by changes in procurement strategies and supply chain relationships as a result of the separation and acquisition activities.

Next Steps

• Teleflex will continue to evaluate strategies to mitigate tariff exposure.
• The company will continue to pursue the separation of Teleflex into RemainCo and NewCo.
• Teleflex will actively explore all options for NewCo, including a potential sale.
• The company expects to close the BIOTRONIK Vascular Intervention acquisition by the end of the third quarter of 2025.
• Full market release of the AC3 RangeTM IABP in the United States is expected in the second quarter of 2025.

Key Dates

Keywords

Teleflex, financial results, revenue, earnings per share, guidance, tariffs, share repurchase, separation, NewCo, Vascular Intervention, BIOTRONIK, medical devices